LEO Pharma offers Taclonex to eligible uninsured

February 15, 2012

LEO Pharma Inc., the Parsippany-based U.S. subsidiary of Denmark’s LEO Pharma A/S, is offering a Patient Assistance Program to provide medication to eligible uninsured patients suffering from plaque psoriasis.

Parsippany, N.J. - LEO Pharma Inc., the Parsippany-based U.S. subsidiary of Denmark’s LEO Pharma A/S, is offering a Patient Assistance Program to provide medication to eligible uninsured patients suffering from plaque psoriasis.

The LEO Patient Assistance Program will provide Taclonex Ointment (calcipotriene 0.005 percent, betamethasone dipropionate 0.064 percent) and Taclonex Scalp Topical Suspension (calcipotriene 0.005 percent, betamethasone dipropionate 0.064 percent) at no cost to eligible plaque psoriasis patients who receive a prescription. Applicants must be without public or private health insurance and earn less than or equal to 300 percent of the federal poverty guidelines and meet all other eligibility criteria.

According to a company statement, Taclonex Ointment and Taclonex Scalp Topical Suspension are the only available once-daily prescription combination therapy treatments for plaque psoriasis and scalp plaque psoriasis.

The company instructs interested patients to obtain an application form from their physician (or call 855-LEO-4YOU), complete the appropriate section and have their doctor do the same, then submit the form via fax or mail as specified on the application.

Accepted patients will be able to receive Taclonex Ointment and Taclonex Scalp Topical Suspension at their prescribing practitioner’s office.

Go back to the Dermatology Times eNews newsletter.